Status | Study |
Recruiting |
Study Name: SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes Condition: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Date: 2015-12-07 Interventions: Drug: SF1126 |
Suspended |
Study Name: Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer Condition: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Date: 2014-08-21 Interventions: Other: Cytology specimen Corre |
Active, not recruiting |
Study Name: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Condition: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Date: 2014-01-10 Interventions: Drug: sorafenib tosylate Given |
Active, not recruiting |
Study Name: PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Condition: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Date: 2013-03-20 Interventions: Drug: PI3K inhibitor BKM120 Gi |
Terminated |
Study Name: Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer Condition: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Date: 2012-02-03 Interventions: Biological: talactoferrin Give |
Completed |
Study Name: TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck Condition: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Date: 2011-03-21 Interventions: Drug: TLR8 agonist VTX-2337 Gi |
Active, not recruiting |
Study Name: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Condition: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Date: 2011-03-08 Interventions: Biological: cetuximab Given IV |
Active, not recruiting |
Study Name: Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck Condition: Head and Neck Cancer Metastatic Squamous Neck Cancer With Occult Prima Date: 2009-12-10 Interventions: Drug: lapatinib ditosylate Giv |
Completed |
Study Name: Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Condition: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Date: 2009-07-14 Interventions: Biological: cetuximab Given IV |
Terminated |
Study Name: Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck Condition: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Date: 2009-05-20 Interventions: Drug: sunitinib malate Given o |